TR
Alzex Neuropharma Inc.
TRRI · OTC
$0.00 +0.00% (+$0.00)
Piotroski F-Score Weak
1/9Valuation
-
N/A P/FCF N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A Debt/Assets N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
50 /100
Moderate Beta -4.12x
EPS volatility N/A
Profitable years N/A
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na TRRI
Online
Sector
Basic Materials
Industry
Other Precious Metals
CEO
Robert W. Rosner
Employees
11
Headquarters
Las Vegas